Myomo (MYO) investor relations material

Business highlights and market opportunity

• Focuses on wearable medical robotics for upper limb paralysis, targeting a large unmet need with first-mover advantage and strong competitive position.

• Medicare reimbursement and new payer contracts have expanded patient access, doubling the addressable market among seniors.

• U.S. prevalence population is 3.8 million, with 400,000–800,000 qualifying for the device and 40,000–80,000 new potential patients annually.

• MyoPro device is non-invasive, uses proprietary brain-computer interface technology, and is protected by 35 patents through 2042.

• Multi-billion dollar market opportunity with Medicare reimbursable price of $68,000 per device.

Distribution, reimbursement, and growth strategy

• Three distribution channels: direct-to-patient advertising, MyoConnect referral program with 150+ rehab hospitals, and orthotics/prosthetics clinics.

• Medicare coverage since April 2024 and contracts with major insurers have increased covered lives to over 100 million.

• Shift to recurring patient sources, with 49% of Q1 revenues from these channels, up from 25% a year ago.

• International revenues, especially in Germany, are growing 30–40% annually; O&P channel revenues up 70% year-over-year in Q1.

• Ongoing RCT at University of Utah to further support reimbursement and market access.

Financial performance and operational efficiency

• 2025 revenue was $40.9 million (25% growth); 2026 guidance is $43–$46 million.

• Q1 2026 revenue was $10.1 million, gross margin 68.2%, and operating loss $3.2 million, with net loss $3 million.

• Operating expenses down 1% year-over-year; cost reductions include launch of MyoPro Mobile App and insourcing manufacturing.

• Cash and investments at $15.7 million, debt of $12.5 million at 11.75% interest, interest-only until May 2027.

• Long-term goal: $100 million annual revenue, 70% gross margin, positive EBITDA and cash flow, with recurring sources as majority of revenue.